Canadian Healthcare Company’s Top Officials Charged in Decade-Long Drug Smuggling Scheme
An Arrest Years in the Making
Federal authorities have arrested a top executive of CANARX, a Canadian healthcare company, on charges of smuggling and conspiracy tied to the illegal importation of prescription drugs into the United States. John Thomas Howard, treasurer and a director of CANARX, was arrested on Sunday on smuggling and conspiracy charges, according to court records. Beyond conspiracy and smuggling, the arrest warrant said John Thomas Howard was charged with introducing misbranded drugs into interstate commerce and illegal drug importation.
Bob Howard, his brother and the president and a director of CANARX, is also wanted in the federal investigation, according to an affidavit from Dustin Dobbs, a special agent with the FDA’s Office of Criminal Investigations — though he has not yet been taken into custody. The company’s general counsel, Joseph Morris, told reporters in a statement: “The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court.”
A Scheme Spanning Nearly a Decade
The criminal complaint covers activities from February 22, 2017, through April 15, 2026, as regulators increased enforcement against offshore drug procurement. The affidavit does not specify which medications the agency believes were illegally imported. What prosecutors do allege is that the company ran supply channels that were never authorized by the pharmaceutical manufacturers producing those medications.
CANARX, founded in 2002 and based in Windsor, Ontario, Canada, described its business on its website as the first international prescription provider for the U.S. and the safest such program in the industry. The company said it sources its medications from Canada, the United Kingdom, Australia and New Zealand. But federal investigators say the reality was far less safe than the company’s marketing suggested. In 2023, the FDA seized medication being shipped by CANARX that it said was potentially misbranded and counterfeit, according to an email sent to a patient obtained by reporters.
Warnings Ignored for Years
The company has been under FDA scrutiny for several years. In 2019, the FDA sent a warning letter to the company, saying it was operating “in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs.” In response, CANARX’s general counsel argued the company was not misleading patients, but agreed to stop importing drugs that need to be administered by a doctor. That concession apparently did little to satisfy federal investigators, who continued building their case for years afterward.
CANARX was featured in a media investigation last year that revealed how the company and others known as alternative funding programs, or AFPs, are becoming more pervasive around the U.S. as drug costs skyrocket. The case targets the AFP business model, which has faced increasing scrutiny for bypassing authorized pharmaceutical supply chains to reduce employer costs. The appeal is easy to understand — employers and employees desperate to cut prescription costs have turned to these programs as a lifeline. But federal law draws a sharp line between individual importation and the kind of large-scale commercial operation prosecutors say CANARX was running.
What Comes Next
The FDA does allow Americans to import medications for individual use in some cases if the drug is not available domestically. Commercial-scale importation without manufacturer authorization is a different matter entirely under federal law. A Gilead spokesperson said the company “has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain,” adding, “We welcome the government’s efforts to hold accountable those whose conduct may put patients at risk.”
With Bob Howard still at large and no plea yet entered by his brother, this case is far from resolved. The arrest signals that federal agencies are sharpening their focus on the AFP industry as a whole — not just one company. As prescription drug prices remain a flashpoint in American healthcare, the government’s willingness to pursue criminal charges against executives, rather than simply issuing warning letters, marks a significant escalation that the entire alternative drug importation industry will be watching closely.


